Chronic Lymphocytic Leukemia Market To Grow Despite Biosimilar Wave

 
• By Lubna Ahmed

The chronic lymphocytic leukemia market is set to increase in size over the next decade despite an anticipated influx of biosimilars, new research by Datamonitor Healthcare finds. AbbVie/J&J's Imbruvica will remain the leading product, but the need for safe and effective therapies for relapsed and refractory CLL patients remains.

Destruction of leukaemia cell, conceptual image. 3D illustration which can be used to illustrate blood cancer treatment
• Source: Shutterstock

More from Anticancer

More from Therapy Areas